Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocomp
by from Morbidity and Mortality Weekly Report (MMWR) on (#6JA9W)
This report describes vaccine effectiveness for the updated COVID-19 vaccine in preventing symptomatic SARS-CoV-2 infection.